Successful tumor eradication primarily depends on generation and maintenance of a large population of tumor-reactive CD8 T cells. Dendritic cells (DCs) are well-known potent antigenpresenting cells and have applied to clinics as potent antitumor therapeutic agents. However, high cost and difficulty in obtaining sufficient amounts for clinical use are the crucial drawbacks of DC-based vaccines. Here, we aimed to develop T cell-based vaccine capable of eliciting potent antitumor therapeutic effects by providing effective costimulatory signals.
Introduction
Activation and expansion of tumor-reactive T-cells population is crucial for destruction and eradication of tumor cells. The activation of tumor-reactive T cells requires additional costimulatory signals provided by antigen-presenting cells (APCs) such as dendritic cells (DCs), along with the binding of T-cell receptors (TCRs) to cognate peptide-MHC (pMHC) complexes [1, 2] . Numerous studies have shown that DCs are efficient cellular adjuvants that express high levels of MHC molecules and costimulatory ligands capable of inducing antigen-reactive T-cell responses, and genetically modification with immunostimulatory molecules, such as additional costimulatory ligands CD70, CD40L, and FLT3L, elicited enhanced T-cell responses in vitro and in vivo [3] [4] [5] . However, though DC-based cellular vaccines have been proven to be safe and immunogenic in cancer patients, DCs are present in limited amounts in human peripheral blood cells, and it is difficult to obtain cells sufficient for clinical applications, making it difficult to apply genetic modifications for use as a cell adjuvant [6, 7] .
For some time, numerous groups including us have explored to identify reliable autologous APC sources as an alternative for DC-based immunotherapy. Several studies have demonstrated that ex vivo-activated B cells using inflammatory cytokines, CD40L, and Toll-like receptor ligands possess a great ability to prime and expand antigen-specific T cells, resulting in in vivo therapeutic antitumor immunity [8] [9] [10] . In other reports, B cells genetically modified to express the costimulatory molecules, and B cells loaded with -galactosylceramide have synergistically amplified T-cell proliferation as efficiently as DCs in vitro and induced a wide range of adaptive immunity against tumor cells [11, 12] . Furthermore, ex vivo-activated  T cells have been proposed as an alternative APC possessing efficient antigen-presenting capabilities that subsequently lead to effective antitumor immunity [13] . CD4 T cells have also been achieved Korean Cancer Association This article is protected by copyright. All rights reserved.
as promising alternative APCs capable of presenting antigenic epitopes to naïve cells, evoking functional memory CD8 T-cell responses [14] [15] [16] .
It is evident that naïve T-cell priming and activation depend in great part on costimulatory signals derived from binding to their ligands expressed on APCs, along with interaction of TCRs and the pMHC complexes [1, 17] . Manipulation of costimulatory ligands on cells has been shown to confer immune-stimulatory function to further enhance and extend the activation of T cells against subsequent tumor challenge [18, 19] . We previously reported that the transient expression of ex-vivo transcribed CD80 and 4-1BBL RNA on CD4 T-cells augments their APC function, resulting in significant therapeutic antitumor effects [16] . In this study, we evaluated the applicability of genetically modified CD8 T cells with costimulatory ligands CD70, CD80, OX40L, and 4-1BBL using recombinant retroviruses to serve as an alternative source of autologous APCs. Our results showed that sustained expression of costimulatory molecules can enhance APC function, and the results from mouse tumor models demonstrate the higher efficiency of CD8 T cells endowed with costimulatory CD70 in inducing effective antigenspecific CD8 T-cell responses.
Materials and Methods

Mice and cell lines
Female C57BL/6 (B6) mice, aged 6 to 8 weeks, were purchased from Orient Bio (Seongnam, Korea). B6.Cg (Pmel-1) congenic (CD90.1) transgenic mice were obtained from Jackson Laboratories (Sacramento, CA), and bred in our animal facilities under specific pathogen-free conditions. Murine EL4 and B16F10 melanoma cell lines were obtained from 6 Korean Cancer Association This article is protected by copyright. All rights reserved.
the American Type Culture Collection (Manassas, VA), and Plat-E retroviral packaging cells were purchased from Cell Biolabs (San Diego, CA). All cell lines were cultured as recommended by the provider.
Peptides, antibodies, and reagents
Synthetic peptides representing the CD8 T-cell epitopes Trp2180 (SVYDFFVWL), hgp10025 (KVPRNQDWL), mgp10025 (EGSRNQDWL), Trp1455 (TAPDNLGYA), the heteroclitic analog Trp1455/9M (TAPDNLGYM), and Ova55 (KVVRFDKL) were purchased >80% pure from A&A Labs. Monoclonal anti-mouse CD40 (FGK45.5) and anti-4.1BB/CD137 (2A)
were prepared from hybridoma culture supernatants. Other antibodies (Abs) for in vivo use in mice, anti-OX40/CD134 (OX86), anti-PD-L1 (10F.9G2), anti-CD8 (2.43), anti-CD4 (GK1.5), and anti-NK1.1 (PK-136) were purchased from BioXCell (West Lebanon, USA). High molecular weight poly-IC was purchased from Invivogen (San Diego, CA), and recombinant cytokines were purchased from PeproTech (Rocky Hill, NJ).
Production of recombinant retroviruses encoding costimulatory ligands
The cDNAs for mouse CD70, CD80, OX40L, and 4-1BBL were obtained from total RNA extracted from matured DCs and were amplified by reverse transcription-polymerase chain reaction (RT-PCR). The PCR products were cloned into the retroviral vector pMP71with Not  and EcoR  sites, and sequenced to determine the possible Taq polymerase errors. For generation of recombinant retroviruses encoding the costimulatory ligands, 5×10 6 Plat-E cells were seeded in a 100-mm culture plate coated with 5 μg/mL of poly-L-lysine (Sigma, St. Louis, MO).
Twenty hours later, 12 μg cloned pMP71 plasmid and retrovirus packaging plasmids (6.3 μg 7 Korean Cancer Association This article is protected by copyright. All rights reserved. pCL-Eco) were simultaneously transfected into Plat-E cells using lipofectamine2000 (Invitrogen, Carlsbad, CA), following the manufacturer's instructions. Two days later, the recombinant retroviruses were harvested and titrated into 293T cells, which were then used for the transduction experiments.
Transduction of recombinant retroviruses encoding costimulatory ligands into in vitro-
activated T-cells
CD8 T cells were obtained using MACS anti-CD8 microbeads (Miltenyi, Auburn, CA).
For in vitro pre-activation, CD8 T cells were co-cultured at 2.5×10 5 cells per well in 96-well plates using T-Cell Activation/Expansion Kit (Miltenyi) in the presence of 100 IU/mL human interleukin 2 (hIL-2). Eight hours later, the supernatant was discarded, followed by addition of recombinant retroviruses encoding costimulatory ligands individually (Mulltiplicity of infection=0.5). CD8 T cells transduced with GFP were referred as mock-control (GFP-T). Cells were centrifuged at 2,500 rpm for 1 hour at 25°C in the presence of 8 μg/mL polybrene (Sigma), and replaced with the above-described culture medium containing a 10 μg/mL peptide(s).
Sixteen hours later (overnight), genetically modified and antigen-loaded CD8 T cells obtained were used for vaccination.
In vitro proliferation assays
Pmel-1 T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE; Molecular Probes, Eugene, OR) at a final concentration of 5 μM for 15 minutes. For in vitro proliferation, 2×10 5 Pmel-1 T cells were co-cultured with 4×10 4 CD8 T cells expressing indicated costimulatory ligands that were irradiated 1,300 rad. After 3 days, cells were stained with CD90.1 (for Pmel-1 cells) and analyzed using flow cytometry. Cell proliferation was calculated using the 8 Korean Cancer Association This article is protected by copyright. All rights reserved.
Proliferation Wizard Model of Modifit LT software (Verity Software House, Topsham, ME).
Immunization
The mice were immunized intravenously with 2×10 6 peptide-loaded CD8 T cells that were modified to express additional costimulatory ligands, as indicated. In some instances, the mice received three booster immunizations every 4 days. Some mice were immunized intravenously with 2×10 6 DCs that were pulsed with 10 μg/mL peptide for 16 hours for comparison. DCs were prepared as described previously [3] . Variously conditioned CD8 T cells and DCs were mixed with 10 μg poly-IC prior to injection, and 7 days later mice received an intravenous TriVax-boost immunization consisting of 150 µg synthetic peptide(s), 50 µg poly-IC, and 100 µg anti-CD40 Abs. In adoptive cell transfer (ACT) setting, mice were injected intravenously with 5×10 6 splenocytes from naïve Pmel-1 mice, and vaccinated one day after ACT. For PD-L1 blockade, anti-PD-L1 Abs were administered intraperitoneally (200 µg/dose) on days +1 and +3 after each immunization (prime and boost).
Evaluation of immune responses
For measuring antigen-specific CD8 T-cell responses, tumor-infiltrating lymphocytes or splenocytes were incubated with 1 g/mL peptide and 1 g/mL GolgiPlug (BD Bioscience, San Diego, CA) at 37°C. After 6 hours, the cells were stained for intracellular interferon γ (IFNγ) using fluorescence-conjugated antibodies against MHC class II, CD8a, and IFNγ, as per the directions provided by the vendor (BD Bioscience). For CD107a/b mobilization shift assay, 2.5 μg/mL of fluorescence-conjugated anti-CD107a and CD107b antibodies were added at the beginning of the stimulation period. For the in vitro T-cell recognition, IFNγ-EliSpot assays 9 Korean Cancer Association This article is protected by copyright. All rights reserved.
(Millipore, Burlington, MA) were performed using freshly isolated CD8 T cells (Miltenyi) from the spleen. Peptide-pulsed or un-pulsed EL4 cells were used as targets cells.
Evaluation of antitumor effects
To assess the therapeutic effects, mice were inoculated subcutaneously with 1×10 5 B16 cells in the rear flank; the first immunization, consisting of 2×10 6 appropriate peptide-loaded CD8 T cells expressing indicated costimulatory ligands, was administered intravenously 3 or 7 days later. Seven days later, the mice received identical CD8 T cells or a TriVax booster immunization as indicated. For in vivo depletion, each mouse received intraperitoneal administrations of 200 µg Abs against NK1.1, CD4, and CD8 on days -3 and -1 before the prime-boost immunizations.
Depletions were confirmed with blood samples using flow cytometry (data not shown). Tumor growth in individual tagged mice was monitored every 3-4 days by measuring two opposing diameters with a set of calipers. Mice were euthanized when the tumor area reached >400 mm 2 .
Results are presented as mean tumor size (area in mm 2 ) ±standard deviation for every treatment group at various time points until the termination of the experiment.
Single-cell preparation
B16 tumors were dissected and chopped into 2-5 mm sizes and incubated with 300 g/mL collagenase-D, 20 g/mL hyaluronidase, and DNase-I (Sigma-Aldrich). After 1 hour, the tissues were dissociated using the gentleMACS Dissociator (Miltenyi) and filtered using 70-μm nylon mesh. Intracellular co-staining of Foxp3 was conducted as per the instructions provided by vendor (eBioscience, San Diego, CA).
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Statistical analyses
Statistical significance to assess the numbers of antigen-specific CD8 T cells was determined by unpaired Student's t test. Tumor sizes between two populations throughout time were analyzed for significance using 2-way ANOVA test. The results are representative of data obtained from at least two independent experiments. All analyses and graphs employed Prism 5.01 software (GraphPad, San Diego, CA).
Ethical statement
All animal research was conducted in accordance with our institutional animal care and use committee guidelines.
Results
Induction of antigen-specific CD8 T cell responses with genetically modified CD8 T cell
To express the costimulatory ligands, T cells were transduced with recombinant retroviruses encoding CD70, CD80, OX40L, and 4-1BBL (hereafter referred to as CD70-T, CD80-T, OX40L-T, and 4-1BBL-T cells, respectively), and surface expression of the costimulatory ligands on CD8 T cells and cell viability after transduction was analyzed.
Phenotypic analysis of ex-vivo activated CD8 T cells was also examined for comparison, exhibiting that all costimulatory ligands were unaffected (data not shown). In vitro transduction efficiency of the individual retroviruses revealed that the levels of the costimulatory ligands expression on CD8 T cells were subsequently increased, and all modified CD8 T cells were viable after transduction ( Fig. 1A and B ). Next, we evaluated the effector T-cell stimulatory Korean Cancer Association This article is protected by copyright. All rights reserved. 
Effects of peptide-based booster Immunization after priming with peptide loaded
CD70-T Vaccines
The above observations indicate that CD8 T cells genetically modified to express additional costimulatory ligand CD70 exhibit augmented APC function as with DCs, and an enhanced Korean Cancer Association This article is protected by copyright. All rights reserved.
ability to stimulate antigen-specific T cells, resulting in delayed tumor growth in vivo. However, we believed that the homologous prime-booster CD8 T-cell immunizations were not sufficient for activating and expanding tumor-reactive CD8 T cells capable of recognizing and destroying tumor cells effectively. Thus, we assessed heterologous CD70-T prime_TriVax (non-infectious peptide-based vaccine) booster immunization regimen to improve immune response of cellular vaccination. To evaluate the role that each of the components of TriVax in the secondary expansion of antigen-specific CD8 T cells, mice received booster immunization after peptideloaded CD70-T priming vaccination. As shown in Fig. 2A and B, TriVax vaccine containing agonistic Abs (anti-OX40, anti-4-1BB, or anti-CD40) was significantly superior to the peptide plus poly-IC only, and the functional activity of freshly isolated CD8 T cells from immunized mouse was evident against both peptide-pulsed EL4 and B16 tumor cells. Moreover, anti-OX40 and 4-1BB Abs was not as effective as anti-CD40 to enhance the magnitude and quality of Tcell responses.
Therapeutic antitumor effects of CD70-T prime_TriVax boost vaccination against established B16 melanoma
Next, we assessed whether CD70-T prime_TriVax boost (CD70-T_TriVax) vaccination could induce similar frequency of antigen-specific CD8 T cells as that of DC-based vaccination.
As shown in Fig. 3A Depletion of NK cells had moderate, but not significant effects on the therapeutic benefit.
Interestingly though, the administration of anti-CD4 Abs in Trp1455/9MCD70-T_TriVax vaccination strategy enhanced the therapeutic efficacy, implying that the elimination of CD4 T cells may contribute to inhibit tumor growth. These overall results suggest that priming with CD70-T vaccination is as efficient as DC-based priming in combination of TriVax booster vaccination regimen, resulting potent therapeutic antitumor effects.
Enhanced therapeutic efficacy of CD70-T_TriVax vaccination along with PD-L1 blockade
Tumor size may impact the therapeutic efficacy of antitumor T-cell immunity; therefore, we evaluated the therapeutic benefits of CD70-T_TriVax vaccination regime against 7-dayestablished (more advanced) B16 melanoma. Under these circumstances, mice that received Trp1455/9MCD70-T_TriVax vaccination had also substantially reduced tumor progression as in DC-based prime vaccination in comparison to that of mock-GFP-T prime vaccination ( Fig. 4A ).
Moreover, we assessed whether in vivo PD-L1 blockade could potentiate the therapeutic efficacy of Trp1455/9MCD70-T_TriVax vaccination in more advanced B16 melanoma. As shown Korean Cancer Association This article is protected by copyright. All rights reserved. 
Effective antitumor CD8 T cell response of multi-epitope-loaded CD70-T_TriVax immunization
One of the potential hurdles of cellular vaccines using single T-cell epitope vaccines is the risk of selecting tumor escape variants. In view of this, we explored whether priming using CD70-T-cells loaded with several peptides followed by multi-peptide TriVax would generate a Korean Cancer Association This article is protected by copyright. All rights reserved. concurrent, multivalent CD8 T-cell response. For these experiments, we added two more T-cell epitopes derived from the melanosomal antigens, Trp2180 and hgp10025. As shown in Fig 
Effects of CD70-T vaccination in antitumor efficacy of adoptive T-cell therapy
Although cells in such small amounts that it is difficult to obtain sufficient cells for clinical applications, and thus there are difficulties in making genetic modifications to use as cell adjuvants [7] . In this aspect, our findings provide a promising preclinical strategy in which using genetically modified CD8 T cells co-expressing CD70 priming followed by TriVax-boost immunization eliciting substantial antitumor effects in a B16 melanoma model. In the clinical realm, we and strategies for generating an amplified number of antigen-specific high-avidity T cells to induce potent immune anticancer immunity to various malignancies. We have also shown a promising vaccination strategy to achieve high levels of tumor-reactive CD8 T-cell responses by heterologous combined administration of antigen-loaded DCs and TriVax booster vaccination [3] . With this regard, we pursued to evaluate heterologous CD70-T_TriVax vaccination strategy, Figs. 4C and 5E ). Our results also demonstrate that CD70-T_TriVax strategy allows simultaneous induction of CD8 T-cell responses to multiple epitopes derived from different melanosome antigens, which elicits a significantly improved therapeutic effect in comparison to that of CD70-T_Trivax using a single antigenic peptide (Fig. 5C ). It is wellknown that a variety of immunosuppressive mechanisms in tumor sites are involved in promoting selective outgrowth of new subclones that are defective on the expression of immunogenic antigens, leading to become more heterogeneous subsets in a wide range of tumors [31] . Thus, our multi-antigen-targeting CD70-T_Trivax strategy capable of inducing large numbers of multivalent CD8 T cells potentiates the applicability of these regimes to elicit significant therapeutic antitumor benefits along with PD-L1 blockade, which exhibited the amplified frequency of tumor-infiltrating T cells in tumor sites.
Lastly, we assessed whether CD70-T vaccination could drive effective ACT against established B16 melanoma in the absence of concomitant additional procedures (high-dose IL-2 and/or lymphodepletion). In our results, ACT followed by DC-based or genetically modified T-cell-based vaccination increased Pmel-1 T-cell numbers; however, effective antigen-specific CD8 T cells were expended only in DC-based and CD70-T-based vaccination (Fig. 6 ). More interestingly, the frequency of tumor-infiltrating Pmel-1 T cells augmented only in CD70-Tbased vaccinated mice (Fig. 6E ). Our results also reveal that a single cellular vaccination Korean Cancer Association This article is protected by copyright. All rights reserved. strategy after ACT may not sufficient to obtain sufficient therapeutic benefits, and the combination of CD70-T_TriVax with ACT strategy was able to expand large numbers and longlasting Pmel-1 cells, eliciting substantial therapeutic antitumor effects with enhanced tumorinfiltrating Pmel-1 T cells.
Overall, our findings suggest that in vitro expanded CD70-T could serve as an alternative 
